Fig. 3. Current multidisciplinary treatment of TNBC, including neoadjuvant chemotherapy plus immunotherapy, surgery and radiation, and adjuvant treatment with ongoing immunotherapy.

Adjuvant PARP inhibitors are given for those with germline BRCA1 or 2 mutations and capecitabine for those with residual disease, although optimal integration in the immunotherapy era is uncertain. In blue neoadjuvant treatment; in green adjuvant treatments. *only for germline carriers of BRCA1-2 mutations. Figure includes modified templates from Servier Medical Art (smart.servier.com).